Dietary Intervention in ADPKD on Tolvaptan
common.study.values.description
“Dietary Intervention in ADPKD on Tolvaptan”
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD. Tolvaptan is an arginine vasopressin receptor antagonist which has been shown to decrease the progression of ADPKD. The main side effect of this treatment is increased urine output which leads to cessation of therapy in about 20% of patients. Low solute (low sodium, low protein) diet may alleviate this side effect. This is a single arm before / after study of dietary intervention on urine output and quality of life in ADPKD patients on a stable dose of tolvaptan.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Dietary
Low sodium, low protein dietary recommendation
participant.views.study.view.additional
participant.views.study.view.scientific-title
Dietary Intervention in Patients With ADPKD on Tolvaptan: Urine Output and Quality of Life
common.study.values.clinical-trial-id
NCT03858439
participant.views.study.view.id
dPNKya
